Cell therapy

#Cancer #CAR-T #Cell therapy

Cancer therapy guide available to download

This guide examines how cell and gene therapy transform cancer treatment. While cell therapies like CAR-T are promising cancer treatments, many challenges remain, including improving responses in blood cancers and efficacy in solid tumours. This new cancer therapy guide from 10x Genomics will outline: Cutting-edge single cell and spatial analysis technologies… Read More

#News

#AI / data analytics / healthtech / informatics #BioELN #Cell therapy

Tracking inputs that go into developing cellular therapeutics – Webinar

Cellular therapeutics like CAR-T have revolutionised cancer treatment and hold immense promise in other areas of unmet medical need. Developing a new therapeutic cell line is no small task and requires the design and tracking of molecular tools, viral vectors, pluripotent stem cells and more. With projects spanning weeks and… Read More

#News

#AI / data analytics / healthtech / informatics #BioELN #Cell therapy

Webinar: Next generation BioELN

Cellular therapeutics like CAR-T have revolutionised cancer treatment and hold immense promise in other areas of unmet medical need. Developing a new therapeutic cell line is no small task and requires the design and tracking of molecular tools, viral vectors, pluripotent stem cells and more. With projects spanning weeks and… Read More

#News

CAR-T cell
#AI / data analytics / healthtech / informatics #BioELN #Cell therapy

How to track inputs that go into developing cellular therapeutics

Cellular therapeutics like CAR-T have revolutionised cancer treatment and hold immense promise in other areas of unmet medical need. Developing a new therapeutic cell line is no small task and requires the design and tracking of molecular tools, viral vectors, pluripotent stem cells and more. With projects spanning weeks and… Read More

#News

#AI / data analytics / healthtech / informatics #BioELN #Cell therapy

Next generation BioELN: how it can accelerate cellular therapy discovery

Cellular therapeutics like CAR-T have revolutionised cancer treatment and hold immense promise in other areas of unmet medical need. Developing a new therapeutic cell line is no small task and requires the design and tracking of molecular tools, viral vectors, pluripotent stem cells and more. With projects spanning weeks and… Read More

#News

#AI / data analytics / healthtech / informatics #BioELN #Cell therapy

Webinar: Accelerating cellular therapy discovery with BioELN

Cellular therapeutics like CAR-T have revolutionised cancer treatment and hold immense promise in other areas of unmet medical need. Developing a new therapeutic cell line is no small task and requires the design and tracking of molecular tools, viral vectors, pluripotent stem cells and more. With projects spanning weeks and… Read More

#News

#Biotherapeutics #Cell therapy #Gene editing #Immunotherapy #T-Cells

Atara Biotherapeutics’ plans to tackle MS with Epstein-Barr Virus

Over the last decade, groundbreaking chimeric antigen receptor (CAR) T-cell immunotherapies have become a well-established cancer treatment modality. Clinical research continues to demonstrate the encouraging potential this approach holds for treating a wide array of conditions while increasing safety, tolerability, and efficiency in manufacturing. Atara Biotherapeutics, a California-based biotechnology company,… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#CAR-T #Cell therapy #Drug screening #Drug targets #Flow Cytometry #Tumour

How to assess the safety profile of potential CAR targets 

CAR T cell technology provides the foundation for established immunotherapies against certain types of blood cancer and holds great promise for the fight against many solid tumours too. One major drawback of conventional CAR T cell technology, which relies on a single target antigen, is the lack of tumour-associated antigens (TAAs) that… Read More

#News #Trending News

#Cell therapy #Technology

The magic of cell therapy 

Listen to this article on the DDW Podcast: Marjie Hadad talks to cell therapy expert and Kadimastem CEO Asaf Shiloni about the potential of cell therapy.  “I am attracted to cell therapy because traditional medicine has reached its limitation in treating the ailments of the 21st century,” says Asaf Shiloni, 20-year biotechnology executive, cell therapy expert and CEO… Read More

#Exclusive Content #Opinion

#Assays #Biotechnology #Cell and gene therapy #Cell therapy #iPSC

Ncardia secures $60+ million for its iPSC Offerings 

Ncardia, developer of stem cell-based solutions for drug discovery and cell therapy, has secured more than $60 million in capital through a strategic partnership with Kiniciti, a US-based investment platform.  Ncardia’s capabilities include bio-reactor-based scalable manufacturing of iPSC derived cells, assay development, disease modeling, and cell-based screening. … Read More

#News

#Cell therapy #Drug development #Drug discovery #Immunology

Bone marrow backup needed to tackle respiratory infections 

Scientists at the Francis Crick Institute have found how the immune system triggers an ‘emergency’ dendritic cell response during infection, with dendritic cells at the site of infection being reinforced by new cells which travel from the bone marrow.   Dendritic cells have an important role in the… Read More

#News #Trending News

#Cell and gene therapy #Cell therapy #Drug discovery #Funding

bit.bio receives $103 million for human cell production  

Human cell coding company bit.bio has closed a Series B financing of $103 million to accelerate the clinical development of the company’s cell coding technology opti-oxTM, a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells. … Read More

#News

#Biopharma #Cancer research #Cell therapy #Drug discovery #Flow Cytometry #Immuno-oncology #Immunology #Webinar

Learn about immunophenotyping and advanced cell function assays

Advances in treatments for human diseases, including cancer, rely on the ability to gain detailed information into the function, modulation, and variation of the immune system in response to stimuli or immunological challenge. Insights derived from these data have, for example, revolutionised cancer treatment by enabling the development of… Read More

#News

#Biopharma #Cancer research #Cell therapy #Drug discovery #Flow Cytometry #Immuno-oncology #Immunology #Webinar

Deriving context from immunological data with flow cytometry – Webinar

Advances in treatments for human diseases, including cancer, rely on the ability to gain detailed information into the function, modulation, and variation of the immune system in response to stimuli or immunological challenge. Insights derived from these data have, for example, revolutionised cancer treatment by enabling the development of… Read More

#News

#Cancer research #Cell therapy #Therapeutics

First-in-human Phase I trial begun for AML treatment 

GammaDelta Therapeutics has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukaemia (AML). GDX012 is an allogeneic, non-engineered, variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy manufactured from healthy donor blood.  AML is the most common form of acute leukaemia in adults with an… Read More

#News